Report : North America Chemotherapy Induced Peripheral Neuropathy Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – Drug Class (Steroids, Antidepressants, Ant seizure, and Narcotics) and Distribution Channel (Retail Pharmacy, Hospital Pharmacy, and Online Pharmacy)
At 5.3% CAGR, the North America Ready-to-Eat Food Market is speculated to be worth US$ 426.71 billion by 2028, says Business Market Insights
According to Business Market Insights’ research, the North America ready-to-eat food market was valued at US$ 297.89 billion in 2021 and is expected to reach US$ 426.71 billion by 2028, registering an annual growth rate of 5.3% from 2021 to 2028. Surging Preference for Chemotherapy and Burgeoning Clinical Trials for Chemotherapeutic Drugs.
Spending on anticancer drugs is one of the most important factors incurring excess costs in healthcare. Both, chemotherapy and targeted therapy significantly improve the chances of survival among cancer patients, along with improving their quality of life. These therapies may result in the complete remission of a tumor. Owing to these benefits, the demand for chemotherapy has surged with the rising burden of cancer. A study published recently in Lancet Oncology states that the number of patients requiring chemotherapy will increase by 53% from 980,000 to 15 million from 2018 to 2040. Advanced cancer treatments further improve patient survival and increase the number of patients requiring long-term outpatient chemotherapy. More exposure to chemotherapy may result in a greater number of CIPN cases, thereby depriving the chemotherapy-induced peripheral neuropathy market growth.
On the contrary, limited of consolidated guidelines for chemotherapy hurdles the growth of North America ready-to-eat food market.
Based on drug class, the North America ready-to-eat food market is divided into steroids, anti-seizure, narcotics, and antidepressants. The steroids segment held 36.3% market share in 2021, amassing US$ 108.20 billion. It is projected to garner US$ 153.18 billion by 2028 to expand at 5.1% CAGR during 2021–2028.
Based on distribution channel, the North America ready-to-eat food market is categorised into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held 60.3% market share in 2021, amassing US$ 179.67 billion. It is projected to garner US$ 252.00 billion by 2028 to expand at 5.0% CAGR during 2021–2028.
Based on country, the North America ready-to-eat food market has been segmented into the US, Canada, and Mexico. Our regional analysis states that the US captured 93.3% market share in 2021. It was assessed at US$ 277.80 billion in 2021 and is likely to hit US$ 399.79 billion by 2028, exhibiting a CAGR of 5.3% during the forecast period.
Key players dominating the North America ready-to-eat food market are REGENACY PHARMACEUTICALS, INC.; Asahi Kasei Pharma Corporation; Novaremed AG; MAKScientific, LLC; WEX Pharmaceuticals Inc.; Sova Pharmaceuticals, Inc.; Kineta, Inc.; Aptinyx Inc.; Apexian Pharmaceuticals, Inc.; and WinSanTor, Inc. among others.
- In December 2020, Regenacy Pharmaceuticals announced the closing of a $30 million Series A financing. The financing was co-led by Cobro Ventures and Taiwania Capital Management Corporation, with participation from 3E Bioventures Capital, Yonjin Capital, VIVA Biotech Holdings, and TA YA VENTURE HOLDINGS LIMITED, and other undisclosed private investors.
In December 2020, Kineta Inc stated that the first participant in Phase 1 clinical trial of KCP506, an experimental, first-in-class 9/10 nicotinic acetylcholine receptor (nAChR) antagonist in development for the treatment of chronic neuropathic pain
- .Contact Us
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email Id: sam@businessmarketinsights.com